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The development and characterization of
Alzheimer’s disease (AD) animal models
that faithfully recapitulate key components
of the pathogenic process has been a major
research focus for nearly a quarter of a
century. Neuropathologically, AD is char-
acterized by the accumulation of extracel-
lular amyloid-β (Aβ) plaques, intracellular
neurofibrillary tangles (NFTs), synapse
loss, glial cell activation, and neuronal
death. The creation of genetically altered
rodent models has significantly advanced
our understanding of AD pathogenesis,
and many novel therapeutic drugs are cur-
rently in clinical trials as a result (LaFerla
and Green, 2012). Transgenic mouse mod-
els most commonly harbor mutations in
APP and/or presenillin 1—gene muta-
tions that are linked to early onset familial
forms of AD (fAD). Nevertheless, the vast
majority of AD cases (≈95%) are sporadic
(sAD), with an unknown genetic etiology
and underlying cause. Consequently, fAD
models pose a number of problems for the
translation of preclinical drug studies to
human clinical trails.
In a recent study published in The
Journal of Neuroscience, Forny-Germano
et al. (2014) injected soluble Aβ oligomers
(AβOs) into the lateral ventricle of adult
cynomolgus macaques. These primates
hold great potential as models of AD
due to their biological proximity to
humans, relatively large brains, com-
plex behavior, and capacity to gener-
ate human-sequence Aβ that deposits as
plaques in the brain with aging (Heuer
et al., 2012). The authors demonstrated
that AβOs diffuse and accumulate in
memory-related brain regions, causing tau
phosphorylation, NFT formation, synapse
pathology, and astrocyte and microglial
activation. This effect was seen in the
absence of extracellular amyloid plaques
and replicated using 3-month-old Wistar
rats in which a similar profile of pathology
was observed. In accordance with stud-
ies using fAD transgenic mice (Tomiyama
et al., 2010), AβOs did not trigger acute
neuronal cell death; however, unlike fAD
mice the macaques displayed widespread
tau pathology. This phenomenon is only
seen in transgenic mice if a mutation unre-
lated to human AD is introduced into the
tau gene (Lewis et al., 2001). Thus, consis-
tent with the amyloid cascade hypothesis
(Hardy and Higgins, 1992), the authors
demonstrate that an early pathological
species of Aβ is sufficient to trigger an AD-
like disease cascade in a novel nonhuman
primate model of sAD.
Over the past two decades, reports have
suggested that cognitive decline in AD
patients is not proportional to Aβ plaque
load but does correlate with increases in
soluble oligomeric forms of Aβ (Wang
et al., 1999). Moreover, the deposition
of Aβ in spatiotemporally distinct brain
regions is thought to occur in a pro-
gressive, spreading manner (Thal et al.,
2008). However, much of the evidence
for these assertions has come from using
AD transgenic mouse models. In their
paper, Forny-Germano et al. (2014) found
that one injection of 100μg of AβOs,
prepared from synthetic Aβ1−42 peptide,
every three days for twenty-four days was
sufficient to induce AD-like pathology in
macaques aged nine and sixteen years.
They showed that AβOs distributed
and induced pathology in multiple
brain regions, including the neocortex,
hippocampus, striatum, and thalamus
(Forny-Germano et al., 2014, their Figure
3). The authors propose that such progres-
sion represents an AD-like intermediary
stage of pathology, but whether their find-
ings are the result of the diffusion of
solution throughout the brain or the prop-
agation of a disease mechanism remains
unclear.
One possible way of addressing this
would be to inject an oligomeric random
peptide, conjugated to a small peptide
tag (such as poly-histidine), and examine
whether the pattern of immunostaining
is maintained. Interestingly, AβO label-
ing appeared to be intra- and extracel-
lular as measured by the anti-oligomer
NU4 antibody, which does not recognize
monomeric Aβ (Forny-Germano et al.,
2014, their Figure 2); however, data using
APP transgenicmice expressing the E693
mutation, which increases Aβ oligomer-
ization without fibrillization, found that
intraneuronal AβOs alone were suffi-
cient to induce features of AD pathol-
ogy (Tomiyama et al., 2010). Additionally,
intracellular Aβ1−42 aggregation has been
found to precede extracellular accumu-
lation in humans (Mori et al., 2002).
In short, while the results of Forny-
Germano et al. (2014) demonstrate that
AβOs distribute and bind to cells in AD-
related brain regions, they do not estab-
lish whether this represents a universal
response to a foreign peptide or to what
extent intra vs. extracellular AβO depo-
sition is responsible for their subsequent
findings.
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Next, using a range of phosphory-
lated tau antibodies, as well as antibodies
recognizing early conformational changes
in NFT formation, the authors show by
immunostaining, western blotting, and
immune-gold electron microscopy that
AβO injection leads to tau hyperphos-
phorylation, truncation, and aggregation
(Forny-Germano et al., 2014, their Figure
5). These results are particularly strik-
ing owing to their support of the amy-
loid cascade hypothesis in a species that
possesses a far closer approximation of
the human brain than rodents. Indeed,
cynomolgus macaques are naturally highly
resistant to NFT pathology until≈30 years
of age, despite developing Aβ plaques and
cerebral amyloidosis at ≈25 years of age
and having >99% gene sequence homol-
ogy to human tau (Heuer et al., 2012).
However, these experiments do not eluci-
date whether AβOs alone are perpetuat-
ing alterations in tau. Activation of astro-
cytes and microglia occurs in this model,
and neuroinflammation might contribute
more to tau pathology in the disease
cascade than is currently recognized. In
fact, Aβ-induced astrocyte and microglial-
derived soluble factors have been impli-
cated in neuronal tau pathology (Metcalfe
and Figueiredo-Pereira, 2010), as well as
synapse loss (Eroglu and Barres, 2010),
suggesting glial activation may also partic-
ipate in the observed decrease in synap-
tophysin and PSD-95 protein expression
(Forny-Germano et al., 2014, their Figure
11). Consequently, it may prove use-
ful to compare the relative contribution
of AβO deposition, glial activation, and
tau pathology to synapse loss between
this model and existing transgenic mouse
models (Figure 1). It will be crucial to
determine the AβO-induced sequence of
events in this model to assess what cellular
and/or molecular components are directly
modulating tau.
Like many studies using transgenic
mice, the authors report no neuronal cell
death in the macaque brain—measured
by TUNEL staining of the frontal cor-
tex and amygdala (Forny-Germano et al.,
2014, their Figure 10). To confirm this,
it would be necessary to examine cas-
pase activation in their tissue sections, for
one could surmise that such a large quan-
tity of injected foreign protein (100μg
of AβOs) would cause some degree of
neuronal fallout. This finding represents
a wider problem for AD animal models,
in which chronic exposure to Aβ often
does not trigger cell death. Human AD
is characterized by widespread neuronal
loss; therefore, it would be prudent to
test whether long-term exposure of AβOs
eventually generates this hallmark feature
of AD neuropathology. If it does, one can
imagine devising reversibility experiments
aimed at inhibiting pathogenesis before an
identifiable critical threshold for neuronal
death.
Future studies should also explore
whether these macaques show behav-
ioral and/or cognitive impairment. AD
transgenic mice display robust and well-
established deficits in memory-related
task, such as the Morris water maze
(MWM), but significantly less data exists
showing cognitive decline in primatemod-
els of AD. This is due in part to the limited
numbers of animals studied and the long
time period required for them to reach
FIGURE 1 | Illustration depicting relationship between mouse and
macaque models of AD in relation to the amyloid cascade hypothesis.
(A) Transgenic mouse and (B) Cynomolgus macaque model used by
Forny-Germano et al. (2014). Both animals display AD-like pathology and
synapse loss, yet the routes and molecular mechanisms underlying this differ
to ultimately model either fAD or sAD. However, these differences may prove
advantageous to test the efficacy of therapeutic intervention at different
stages in the disease cascade.
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maturity. Plaque density has not been
found to correlate with cognitive decline
in the closely related rhesus macaques,
but studies have shown that recognition
memory decline begins during the late
teenage years, when increased Aβ is seen in
the medial temporal lobe, and progresses
concomitantly with increased Aβ deposi-
tion in the frontal cortex during the ani-
mals’ mid-twenties (Heuer et al., 2012).
Experiments examining whether AβOs are
related to this process would be particu-
larly informative. In addition, it would be
interesting to see if the results of Forny-
Germano et al. (2014) are the same inmale
cynomolgus macaques. The authors used
seven females for their experiments, and
male-female differences might be impor-
tant considering that in rhesus macaques
biosenescence occurs around the same age
at which menopause becomes apparent
(≈25 years); and notably, reports in AD
patients suggest that estrogen may be neu-
roprotective (Correia et al., 2010).
In closing, Forny-Germano et al. (2014)
propose a powerful and unique animal
model that recapitulates core features of
AD neuropathology in a species biologi-
cally close to humans. This may offer a
novel research platform for future mech-
anistic studies aimed at shedding more
light on the amyloid cascade hypothesis, as
well as testing novel diagnostic and ther-
apeutic agents targeting oligomeric Aβ,
hyperphosphorylated tau, and/or neuroin-
flammation in sporadic AD. Key ques-
tions for future studies include: (1)
What are the molecular signals under-
lying AβO-induced tau pathology and
synapse loss? (2) Does chronic expo-
sure of AβOs in macaques lead to neu-
ronal loss and/or cognitive impairment?
(3) At what stage in the disease cascade
would therapeutic intervention provide
the most benefit? Experiments aimed at
addressing these questions will be help-
ful to further characterize and explore this
model.
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